enow.com Web Search

Search results

  1. Results from the WOW.Com Content Network
  2. Prokinetic agent - Wikipedia

    en.wikipedia.org/wiki/Prokinetic_agent

    Activation of a wide range of serotonin receptors by serotonin itself or by certain prokinetic drugs results in enhanced gastrointestinal motility. [3] Other prokinetic drugs may increase acetylcholine concentrations by stimulating the M 1 receptor which causes acetylcholine release, or by inhibiting the enzyme acetylcholinesterase which ...

  3. Diabetes medication - Wikipedia

    en.wikipedia.org/wiki/Diabetes_medication

    Type 2 diabetes mellitus is the most common type of diabetes. Treatments include agents that (1) increase the amount of insulin secreted by the pancreas, (2) increase the sensitivity of target organs to insulin, (3) decrease the rate at which glucose is absorbed from the gastrointestinal tract, and (4) increase the loss of glucose through ...

  4. SGLT2 inhibitor - Wikipedia

    en.wikipedia.org/wiki/SGLT2_inhibitor

    The 2022 American Diabetes Association (ADA) standards of medical care in diabetes include SGLT2 inhibitors as a first line pharmacological therapy for type 2 diabetes (usually together with metformin), specifically in patients with chronic kidney disease, cardiovascular disease or heart failure.

  5. First pass effect - Wikipedia

    en.wikipedia.org/wiki/First_pass_effect

    [1] [2] The effect is most associated with orally administered medications, but some drugs still undergo first-pass metabolism even when delivered via an alternate route (e.g., IV, IM, etc.). [3] During this metabolism, drug is lost during the process of absorption which is generally related to the liver and gut wall. The liver is the major ...

  6. Metformin - Wikipedia

    en.wikipedia.org/wiki/Metformin

    Anticholinergic drugs reduce gastric motility, prolonging the time drugs spend in the gastrointestinal tract. This impairment may lead to more metformin being absorbed than without the presence of an anticholinergic drug, thereby increasing the concentration of metformin in the plasma and increasing the risk for adverse effects.

  7. Bethanechol - Wikipedia

    en.wikipedia.org/wiki/Bethanechol

    The muscarinic receptors in the bladder and gastrointestinal tract stimulate contraction of the bladder and expulsion of urine, and increased gastrointestinal motility, respectively. Bethanechol should be used to treat these disorders only after mechanical obstruction is ruled out as a possible cause.

  8. GLP-1 receptor agonist - Wikipedia

    en.wikipedia.org/wiki/GLP-1_receptor_agonist

    GLP-1 agonists were developed initially for type 2 diabetes. [5] The 2022 American Diabetes Association (ADA) standards of medical care in diabetes include GLP-1 agonist or SGLT2 inhibitor as a first line pharmacological therapy for type 2 diabetes in patients who have or are at high risk for atherosclerotic cardiovascular disease or heart failure.

  9. Domperidone - Wikipedia

    en.wikipedia.org/wiki/Domperidone

    [62] [63] The cause is thought to be blockade of hERG voltage-gated potassium channels. [16] [17] The risks are dose-dependent, and appear to be greatest with high/very high doses via intravenous administration and in the elderly, as well as with drugs that interact with domperidone and increase its circulating concentrations (namely CYP3A4 ...